ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
https://www.facingourrisk.org/research-clinical-trials/study/155/atr-inhibitor-plus-niraparib-study-in-advanced-solid-tumors-and-ovarian-cancer
Clinicaltrials.gov identifier:
NCT04267939 (https://clinicaltrials.gov/show/NCT04267939)
Advanced ovarian cancer or other solid tumors
Study Contact Information:
For additional information, contact: Bayer Clinical Trials by phone: 1-888-842-2937 or by email
About the Study
This study will look at how well how people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to participants who have had their ovarian cancer progress while on a PARP inhibitor.
This study is no longer enrolling people.
This Study is Open To:
This study is no longer enrolling people.
This Study is Not Open To:
This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.